Objective. To investigate the relationship between depressive symptoms and treatment response and disease activity in RA over a 1-year follow-up.
Introduction
Depression is prevalent in RA, with meta-analysis evidence suggesting a 17% point prevalence according to diagnostic interview [1] . Recent evidence has highlighted depression symptoms as a prognostic psychomarker for poor rheumatological outcomes, with symptoms of depression and anxiety associated with worsened disease activity, physical function and reduced response to DMARD and glucocorticoid treatments [2, 3] . Depression is rarely measured in rheumatological research [4] ; assessment of mental health is usually limited to assessment of mental health domains on health-related quality-of-life (HRQoL) questionnaires such as the Medical Outcomes Survey 36-item Short-Form (SF36) [5] or the EuroQol five-dimension scale (EQ5D) [6] .
The development of biologic treatments for RA has revolutionized the management of RA; in comparison with conventional DMARDs, biologics contribute to increased likelihood of disease remission and significantly improve physical function [7, 8] . There is, however, a dearth of research examining the relationship between depression and long-term disease outcomes in RA [3] . The impact of comorbid depression on biologic treatment response has previously been investigated in a US register; the authors reported an association between depressive symptomatology and likelihood of remission at 6-month follow-up, purported to be driven by an association between depression and subjective experiences of disease [9] . Their assessment was limited to a one-item depression comorbidity tick-box, which may result in high false-positive rates due to poor specificity [10] . Analysis of the Norwegian DMARD (NOR-DMARD) database identified an association between depressive symptoms at the start of treatment with biologic or synthetic DMARDs, and reduced risk of remission and higher pain and global assessment at 3-and 6-month follow-up [11] . To date, there is stronger evidence for a relationship between depressive symptoms and subjective experiences of disease such a patient global assessment (PGA) and pain [2, 1113] , contributing to a growing focus on redefining remission in RA [14] .
The present study seeks to examine the longitudinal association between depressive symptoms and treatment response in a UK national register of RA patients starting their first biologic. In comparison with previous research [9] , this study utilizes three measures of depression symptoms: history of depression comorbidity tick-box, the mental health domain of the SF36 and the depression/ anxiety item of the EQ5D, providing an opportunity to investigate the differential relationships between depression symptoms and treatment outcomes based on mental health assessment strategy. The aims are (i) to examine the relationship between baseline depression symptoms and biologic treatment response over 1-year follow-up and (ii) to evaluate the relationship between baseline depression symptoms and disease activity over 1 year.
Methods

Participants
This study presents an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA; [15] ). The BSRBR-RA is a national prospective register of RA patients starting a new biologic, and contains data from 18 421 patients enrolled since its inception in 2001. To be eligible for inclusion in the BSRBR-RA, patients must meet UK guidelines for commencing a biologic: sustained active RA (defined as scoring >5.1 on the DAS28 at two time points a month apart); and failure to respond to conventional DMARDs including MTX over a 56 month time frame [16] . A range of clinical, demographic and psychological assessments are taken at baseline, 6-monthly intervals for the first 3-years of follow-up, and yearly thereafter. We limited our analysis to first biologic exposure only.
Assessments
Depression symptoms
Three measures of depressive symptoms are available in the BSRBR-RA database: upon enrolment, all patients are asked if they have ever had or received treatment for depression, which was used as an indicator of history of depression. The SF36 [5] was used as an assessment of HRQoL between 2001 and 2008, in the first 11 937 enrolled patients. A threshold of 440 on the normed mental health (nMH) subscale of the SF36 has been shown to have a 92.6% sensitivity and 73.2% specificity for identifying depression in patients with RA [17] . Responses to the SF36 were categorized using this threshold, to represent patients with low HRQoL. The EQ5D [6] was introduced to the BSRBR-RA in 2005 and became the only HRQoL assessment from 2010 onwards. The EQ5D has one item specific to mental health, allowing patients to identify whether they are feeling not depressed/anxious, moderately depressed/anxious, or extremely depressed/ anxious today. Evidence suggests that one-item mood screeners have 84% sensitivity and 65% specificity [18] , and this item has been previously used to predict longitudinal DAS28 and HAQ outcomes, and prednisolone treatment response in RA patients [2] .
Treatment response
The primary outcome of interest was 1-year treatment response, measured by the EULAR guidelines [19] . Based on their 1-year EULAR response, patients were categorized into those demonstrating a good treatment response and those with a suboptimal treatment response (no/moderate response).
Disease activity
Secondary outcomes were disease activity (measured via the DAS28), and its composite parts of tender joint count (TJC), swollen joint count (SJC), PGA and ESR, all measured at 1-year follow-up. TJC and SJC underwent square root transformation and ESR data were log transformed for analysis.
Statistical analysis
Although data were available for 3 years of follow-up, only data for the first year of follow-up were included. This ensured a focus on first biologic exposure, eliminating bias introduced by patients switching biologics due to a lack of treatment response. All analyses were conducted on Stata v14 (StataCorp, College Station, TX, USA). Clinical and demographic characteristics of patients having a good treatment response by 1 year were compared with those with no/moderate treatment response using means (S.D.), with statistically significant imbalance determined using t-tests for continuous variables and chisquare tests for categorical data.
Aim 1: the impact of baseline depressive symptoms on 1-year biologic treatment response Logistic regression models were performed in two stages: unadjusted (model 1), then adjusted for age, gender, disease duration, baseline DAS28, baseline HAQ and number of comorbidities (model 2). Logistic regression estimates the odds of a binary outcome (i.e. having a good treatment response), based on several predictor variables (i.e. baseline depression). In all models, baseline depressive symptomatology was entered as the predictor variable: history of depression (yes/no); SF36 nMH subscale (440/>40); EQ5D (no/moderate/extreme). Treatment response at 1 year (none/moderate vs good) was the outcome variable in primary analyses. Odds ratios (ORs), P-values and 95% CIs estimated whether the presence of depressive symptoms at biologic initiation was associated with increased odds of having a good treatment response at 1 year. Multiple imputation was used to address baseline missing data for DAS28, disease duration and HAQ. The relationships between baseline depression and 1-year DAS28, TJC, SJC, PGA and ESR were examined using multilevel longitudinal models, pooling data across the time points (baseline, 6 months and 1 year) [20] . Multilevel modelling handles hierarchically nested data, accounting for missing data and both between-and within-participant variation over time, and multiple imputation was used to address baseline missing data for DAS28, disease duration and HAQ.
Output from multilevel models includes unstandardized maximum likelihood estimates (B coefficients), which estimate the magnitude and direction of change in an outcome variable according to a reference group (no depressive symptoms at baseline). In addition to depressive symptoms as a predictor variable and DAS28 (and its composite parts) as outcome variables, multilevel models included time as a continuous variable coded as 0 at baseline, 1 at 6 months and 2 at 12 months, and the interaction between time and baseline depressive symptoms, to examine whether change over time is different between people with and without symptoms of depression at baseline. A random intercept and random time slope allowed for variation in the baseline level of the outcome and the rate of change in the outcome between individuals. The random effects were allowed to correlate, which means that some control for the baseline level of the outcome is included in the model even though it is not included as a covariate-for example, a positive correlation would allow for increasing variability in the outcome variable over time [21] . Multilevel models were created in two stages: including only baseline depression symptoms, time and an interaction between time and depression symptoms, plus random effects; and additionally adjusting for age, gender, disease duration, comorbidities and baseline physical activity (measured via the HAQ [22] ). Covariates were selected based on theoretical relevance.
BSRBR-RA participants' written consent was obtained according to the Declaration of Helsinki. The BSRBR study has been approved by the North West Multicentre Research Ethics Committee; ethical approval for the BSRBR allows anonymized data to be used for secondary analysis without further approvals. Figure 1 shows the data available for analysis for the primary outcome (treatment response) and secondary outcome (disease activity), in relation to the different methods of depressive symptom measurement. Missing response status/disease activity outcome data at 1 year was associated with increased BMI, and lower baseline DAS28, TJC, SJC, ESR and HAQ, shown in supplementary Table S1 , available at Rheumatology online. Baseline depression symptoms, according to all three measurements available, was not associated with missing outcome data.
Results
Missing data
Participant characteristics
Data from 18 421 patients enrolled in the BSRBR-RA by December 2015 were included in this analysis (Fig. 1) . Table 1 displays baseline demographic, clinical and psychological variables for all patients. The mean age was 56.4 years, 76.4% were female, with a mean disease duration of 12.6 years and mean DAS28 of 6.4. By 6 months, 3638 patients had achieved a good treatment response. At 1 year, a total of 5271 (34.3%) patients had reached a DAS28 of 43.2 and an improvement in DAS28 from baseline of >1.2.
At 1-year follow-up, 17.9% of patients were identified as switching biologic. Biologic switching was significantly higher in patients reporting a history of depression, and depressive symptoms according to the SF36 and EQ5D at baseline (supplementary Table S3 , available at Rheumatology online).
History of depression
In comparison with patients without a history of depression, logistic regression indicated that patients reporting a history of depression have reduced odds (OR = 0.80, 95% CI: 0.69, 0.92) of having a good treatment response by 1-year follow-up after adjusting for covariates (Table 2) .
Using multilevel longitudinal models, patients reporting a history of depression reported significantly lower levels of baseline DAS28 (B = À0.07, 95% CI: À0.12, À0.02) but a significantly lower rate of improvement in DAS28 over time in comparison with patients without a history of depression (Table 3) . Those without a history of depression reported a total improvement in DAS28 of À0.4 at 1 year, whereas patients with a history of depression reported a decrease in DAS28 score of À0.36 between baseline and 1-year follow-up (Table 3) . This significant interaction effect is displayed graphically in Fig. 2 .
Supplementary Tables S3S6, available at Rheumatology online, show the results of the multilevel longitudinal analyses examining the relationship between history of depression status and TJC, SJC, PGA and ESR outcomes, respectively. Patients without a history of depression show significantly reduced improvement in all components over time in comparison with patients with a history of depression.
SF36 nMH subscale
In comparison with patients scoring 440 on the SF36 nMH subscale, logistic regression analysis revealed that those scoring >40, had no significant difference in the odds of having a good treatment response at 1-year follow-up (Table 2) .
According to multilevel longitudinal analysis, there were no differences in baseline DAS28 levels between those scoring 440 and >40 on the nMH subscale, although patients scoring 440 reported a significantly reduced rate of improvement in DAS28 over time in comparison with those scoring >40. Whereas patients scoring >40 on the nMH reduce in DAS28 scores by À0.42 at 1 year, patients scoring 440 show an overall improvement in DAS28 of À0.40 by 1-year follow-up (Table 3) . This significant interaction effect is shown graphically in Fig. 2 .
Supplementary Tables S3S6, available at Rheumatology online, show the results of the multilevel analyses examining the relationship between nMH status and TJC, SJC, PGA and ESR outcomes, respectively. Depressive symptomatology according to the SF36 nMH subscale was not associated with change in PGA or ESR scores over time; however, patients scoring 440 showed reduced improvements in TJC and SJC outcomes in comparison with patients scoring >40.
EQ5D
Logistic regression analysis adjusting for covariates reveals no significant difference in odds of having a good treatment response between patients reporting no depression symptoms and those reported moderate symptoms (OR = 0.85, 95% CI: 0.69, 1.04). In comparison with patients reporting no depression symptoms, those reporting extreme depression symptoms had a significantly reduced odds of a good treatment response at 1-year follow-up (OR = 0.62, 95% CI: 0.45, 0.87) ( Table 2) .
Results of longitudinal multilevel analyses reveal no significant difference between depression symptom groups and baseline levels of DAS28; however, in comparison with patients with no depression symptoms at baseline, those with moderate and extreme symptoms show significantly reduced rate of improvement over time. In comparison with patients with no symptoms of depression according to the EQ5D, who improve by À0.38 at 1-year follow-up, patients with some symptoms and extreme symptoms report reductions in DAS28 of À0.34 and À0.32, respectively, at 1-year follow-up (Table 3 ). The significant interaction between depression symptoms and follow-up time point is displayed graphically in Fig. 2 .
Supplementary Tables S3S6, available 
Discussion
This study found symptoms of depression at baseline to be associated with reduced long-term odds of reaching clinical remission in patients receiving their first biologic drug. This supports previous evidence from the USA and Norway demonstrating reduced likelihood of reaching OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value remission in patients with symptoms of depression at treatment initiation [9, 11] . We also identified prospective associations between baseline depression symptom status and disease activity, with depression symptoms contributing to increased DAS28 over the 12-month follow-up, and impacting change in DAS28 in response to treatment. Examination of the DAS28 components identified associations between depression and both subjective and objective aspects of disease activity; effect sizes did not differ between subjective and objective outcomes, contradicting previous research findings emphasizing the relationship between depressive symptoms and subjective experiences of disease [3, 11, 23] . There are several explanations for this novel finding. Firstly, depression is known to impact health behaviours such as medication adherence [24] , and non-adherence to biologics has been shown to reduce DAS28 treatment response [25] . Whilst adherence data are not collected for all contributors to the BSRBR-RA databset and not available for inclusion in this paper, the role of adherence as a mechanism for this relationship is a valuable area for future research. Secondly, there may be a biological explanation for these findings. Systemic inflammation and elevated cytokines typically associated with RA disease manifestation and disease severity are also identified in people with depressive disorder [2628] . Finally, the large sample size available for this analysis may have provided sufficient statistical power to identify small effect sizes typically unobservable in smaller datasets.
We identified differential effects of symptoms of depression on rheumatological outcomes, based on the depression assessment method. Whereas a history of depression and EQ5D categories were largely predictive of all assessed outcomes, either showing a main effect or modifying change over time, the SF36 was not associated with ESR or PGA. This may be due to these assessments representing different elements of mental health. Ticking a depression comorbidity tick box may indicate a lifetime history of depression, or exposure to mental health treatment, but it provides no time frame or qualifications for endorsement [29] . As the history of depression assessment may include people who have previously received treatment for depression, they may not be experiencing current symptomatology. This measure should be viewed as lifetime depression prevalence, rather than presence of current symptomatology.
The SF36, alternatively, contains multiple items covering a range of psychological symptoms, including happiness, nervousness, calmness, tiredness and participation in social activities [5] and is framed to detect a change from normality within the last month. It may represent a more nuanced perspective of mental health, including positive and negative affect, as well as psychosomatic and behavioural symptoms often associated with chronic illness. We used thresholds based on a validation study [30] , but the high prevalence of depression measured on the SF-36 suggests a lack of specificity, which may have reduced effect sizes due to measurement error [31] . The EQ5D assesses current depressive symptomatology, and although by no means a diagnostic test for depression, representing moderate sensitivity and specificity, the low proportion of patients reporting extreme depression/anxiety is lower than typical prevalence estimates of depression in RA [1] .
This study has used appropriate longitudinal data analysis methodology to examine the long-term relationship between symptoms of depression and biologic treatment response. There is a shortage of high-quality longitudinal investigation in this field, and the evidence that does exist is limited to studies with highly selected samples, suboptimal depression assessments, inadequate adjustment for confounding variables and inappropriate analysis methodologies [3] . The current study uses the largest prospective observational biologics registry in the world to examine   FIG. 2 Fully adjusted interactions between baseline depression symptoms and time on DAS28 outcomes over 12-month follow-up the impact of depression symptoms on outcomes in realworld patients undergoing biologic treatment. Our results are therefore externally valid, representing patients prescribed biologics across the UK-a diverse population.
There are limitations to consider when interpreting these findings. Although providing several interpretations of depression, none of the measurement tools available for baseline depression are gold-standard indicators of the presence of diagnostically ascertained depression. Due to the scarcity with which validated screening tools or diagnostic interviews are utilized to measure depression in RA research [4] , the opportunity to compare three methods in the current paper is helpful; however, given the high prevalence and impact of depression on disease outcomes, symptoms of depression should be routinely measured in rheumatological practice.
We did not adjust our models for treatment type, or previous failure with conventional DMARDs. As all patients are receiving biologics and there is no well-established association between different types of biologic or DMARD on our dependent or independent variables, we chose not to include treatment type as a confounder in our models. No data were available on concurrent mental health treatment, and it is likely that some patients may have been receiving therapy or antidepressant treatments, which may reduce our observed effects.
These results contribute to the growing body of literature highlighting the role depression plays in predicting long-term health outcomes and treatment response in RA. These findings have several implications. Repeated screening and management of mental disorder should be undertaken as part of clinical care. Biologics are expensive [32] , and poor treatment response can result in switching biologics, which can result in further costs [33] . Depression should therefore be routinely measured in RA clinical trials, and in clinical practice.
In conclusion, experiencing symptoms of depression at the start of biologics treatment is associated with reduced treatment response, impacting change over time in disease activity. The management of symptoms of depression in routine care is recommended by the National Institute for Health and Care Excellence (NICE) [34] , and depression is treatable within the context of long-term physical health conditions [3537] . Future research examining the impact of mental health intervention for physical health outcomes may identify whether effectively managing depression can improve treatment response in RA.
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